ABSK091 Food Effect Study in Healthy Subjects

A

Abbisko Therapeutics

Status and phase

Completed
Phase 1

Conditions

Health, Subjective
Food-drug Interaction

Treatments

Drug: ABSK091 tablet

Study type

Interventional

Funder types

Industry

Identifiers

NCT05533788
ABSK091-101

Details and patient eligibility

About

In this study, a single oral dose of the tablet formulation administered under fed conditions will be compared to administration under fasted conditions to assess the effects of a high-fat meal on the rate and extent of absorption and exposure. Study ABSK091-101 is a single-center, Phase 1, open-label, randomized, two-period, two-sequence, and crossover study in healthy subjects.

Enrollment

13 patients

Sex

All

Ages

20 to 45 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Provision of signed and dated informed consent prior to any study specific procedures
  • aged 20 to 45 years, inclusive, at the time of screening
  • male subjects: agree to use an effective method of contraception and not donate sperm for the duration of the study and for 3 months following the last dose of ABSK091
  • female subjects: non-pregnant, non-lactating female subjects who if premenopausal are using adequate birth control, e.g., oral, injectable, transdermal or implanted hormonal contraceptives, vaginal contraceptive ring, intrauterine device/intrauterine system, tubal ligation, vasectomized sexual partner (with confirmed negative sperm counts) or true sexual abstinence. All females must have a negative serum pregnancy test within 7 days and a negative urine pregnancy test within 24 hours prior to dosing with ABSK091
  • have a body mass index (BMI) of 18.5 to 24.9 kg/m2, inclusive, and weigh at least 50 kg and no more than 90 kg, at screening
  • healthy subjects as determined by medical history and physical examination and have clinical laboratory test results within normal reference range for the investigative site, or results with acceptable deviations that are judged to be not clinically significant by the investigator
  • with suitable veins for cannulation or repeated vein puncture
  • are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures

Exclusion criteria

  • Are currently enrolled in a clinical trial involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study
  • Have participated, within the last 30 days, in a clinical trial involving an investigational product. If the previous investigational product has a long half-life, 3 months or 5 half-lives (whichever is longer) should have passed.
  • Have previously completed or withdrawn from this study or any other study investigating ABSK091, and have previously received the investigational product
  • Have a history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the investigational product; or of interfering with the interpretation of data, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study.
  • Have known allergies to ABSK091, related compounds, or any components of the formulation, or history of significant atopy.
  • Have known or ongoing psychiatric disorders that would interfere with study participation as determined by the investigator.
  • Any clinically significant illness, medical/surgical procedure or trauma within 4 weeks of the first administration of ABSK091 .
  • Any clinically significant abnormalities in clinical chemistry, hematology, or urinalysis results as judged by the Investigator.
  • Have an abnormality in the 12-lead ECG that, in the opinion of the investigator, increases the risks associated with participating in the study.
  • Prolonged QT interval corrected for heart rate using Fridericia's formula (QTcF) >450 ms (female >480 ms) or shortened QTcF <350 ms or family history of long QT syndrome.
  • Have an abnormal blood pressure as determined by the investigator.
  • Any positive result on screening for serum hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody and human immunodeficiency virus (HIV) .
  • Any of the following ophthalmological criteria.
  • Known or suspected history of drug abuse as judged by the Investigator.
  • Have used or intend to use over-the-counter or prescription medication , including herbal medications, within 14 days prior to dosing and during the study
  • Plasma donation within one month of screening or any blood. donation/blood loss >500 mL during the 3 months prior to screening
  • Have an average weekly alcohol intake that exceeds 21 units per week (males) and 14 units per week (females), or are unwilling to abide by alcohol restrictions as specified in Section 6.3.2 (1 unit = 12 oz or 360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits)
  • are subjects who currently smoke more than 5 cigarettes per day (or equivalent in tobacco or nicotine products) or are unwilling to abide by smoking restrictions as specified in Section 6.3.2
  • Any intake of grapefruit, grapefruit juice, Seville oranges, Seville orange marmalade or other products containing grapefruit or Seville oranges within 7 days before the first administration of the ABSK091
  • have a current or recent history (<30 days prior to screening and/or <45 days prior to Day -1 in Period 1) of a clinically significant bacterial, fungal, parasitic, viral (not including rhinopharyngitis), or mycobacterial infection
  • have had symptomatic herpes zoster within 3 months of screening
  • have received live vaccine(s) within 3 months of screening, or intend to during the study
  • are unwilling to comply with the dietary requirements/restrictions during the study.
  • have used or intend to use drugs or substances that are known to be strong or moderate inhibitors or inducers of CYP 3A4/5 and/or CYP2D6 within 30 days prior to the first dose and throughout the study.
  • Have a history of, in the opinion of the investigator, excessive methylxanthine use within the previous 6 months, or are unwilling to abide by restrictions as specified in Section 6.3.2. Excessive intake is defined as more than 6 units of caffeine per day; one caffeine unit is contained in the following items: 1 (177 mL) cup of coffee, 1 (355 mL) cup of tea, 2 (355 mL) cans of cola, or 3 oz (85 g) of chocolate
  • Involvement in the planning and/or conduct of the study (applies to Abbisko staff, CRO staff, and staff at the study site)
  • in the opinion of the investigator or sponsor, are unsuitable for inclusion in the study

Trial design

13 participants in 2 patient groups

Fed states in healthy subjects
Other group
Description:
Fed states in healthy subjects
Treatment:
Drug: ABSK091 tablet
Fasted states in healthy subjects
Other group
Description:
Fasted states in healthy subjects
Treatment:
Drug: ABSK091 tablet

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems